Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
GL Beretta, G Cassinelli, M Pennati, V Zuco… - European journal of …, 2017 - Elsevier
Resistance to conventional and target specific antitumor drugs still remains one of the major
cause of treatment failure and patience death. This condition often involves ATP-binding …
cause of treatment failure and patience death. This condition often involves ATP-binding …
[HTML][HTML] Review of therapeutic drug monitoring of anticancer drugs part two–targeted therapies
Most of oral targeted therapies are tyrosine kinase inhibitors (TKIs). Oral administration
generates a complex step in the pharmacokinetics (PK) of these drugs. Inter-individual PK …
generates a complex step in the pharmacokinetics (PK) of these drugs. Inter-individual PK …
Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets
There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM)
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …
Evidence for therapeutic drug monitoring of targeted anticancer therapies
B Gao, S Yeap, A Clements, B Balakrishnar… - Journal of Clinical …, 2012 - ascopubs.org
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of
antibiotics, immunosuppressives, antiepileptics, and other drugs, but its use for traditional …
antibiotics, immunosuppressives, antiepileptics, and other drugs, but its use for traditional …
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance
O Bruhn, I Cascorbi - Expert opinion on drug metabolism & …, 2014 - Taylor & Francis
Introduction: Human ATP-binding cassette (ABC) transporters act as translocators of
numerous substrates across extracellular and intracellular membranes, thereby contributing …
numerous substrates across extracellular and intracellular membranes, thereby contributing …
[HTML][HTML] Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug–drug …
S Peters, S Zimmermann, AA Adjei - Cancer treatment reviews, 2014 - Elsevier
The development of orally active small molecule inhibitors of the epidermal growth factor
receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC) …
receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC) …
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
H Bruckmueller, I Cascorbi - Expert opinion on drug metabolism & …, 2021 - Taylor & Francis
Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …
Variability in bioavailability of small molecular tyrosine kinase inhibitors
M Herbrink, B Nuijen, JHM Schellens… - Cancer treatment reviews, 2015 - Elsevier
Small molecular tyrosine kinase inhibitors (smTKIs) are in the centre of the very quickly
expanding area of personalized chemotherapy and oral applicability thereof. The number of …
expanding area of personalized chemotherapy and oral applicability thereof. The number of …
Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)
I Ieiri - Drug metabolism and pharmacokinetics, 2012 - jstage.jst.go.jp
Recent pharmacogenomic/pharmacogenetic (PGx) studies have disclosed important roles
for drug transporters in the human body. Changes in the functions of drug transporters due …
for drug transporters in the human body. Changes in the functions of drug transporters due …
Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation
S Ueshima, D Hira, R Fujii, Y Kimura… - Pharmacogenetics …, 2017 - journals.lww.com
Objectives During anticoagulant therapy, major bleeding is one of the most severe adverse
effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and …
effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and …